TG Therapeutics, Inc.TGTXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +146.04% | +90.40% | +92.13% | +92.79% | +78.00% |
| Gross Profit Growth | +157.56% | +81.73% | +87.55% | +79.18% | +66.37% |
| EBITDA Growth | +0.00% | +0.00% | +255.61% | +115.59% | +58.68% |
| Operating Income Growth | +0.00% | +0.00% | +295.22% | +136.17% | +68.60% |
| Net Income Growth | +0.00% | +0.00% | +309.75% | +9974.61% | -1.26% |
| EPS Growth | +0.00% | +0.00% | +300.00% | +8866.67% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +293.52% | +12050.00% | -6.67% |
| Weighted Average Shares Growth | +1.50% | +0.32% | +1.39% | +0.22% | -1.57% |
| Weighted Average Shares Diluted Growth | +11.99% | +11.33% | +1.97% | +0.18% | -0.55% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +34.32% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +33.56% | +0.00% | +0.00% |
| Receivables Growth | +152.84% | +192.57% | +176.91% | +129.32% | +136.58% |
| Inventory Growth | +177.37% | +102.99% | +91.03% | +73.56% | +13.70% |
| Asset Growth | +75.28% | +75.90% | +75.12% | +74.91% | +84.05% |
| Book Value per Share Growth | +36.49% | +47.73% | +53.54% | +215.32% | +196.08% |
| Debt Growth | +129.00% | +127.20% | +125.45% | -0.04% | +2.76% |
| R&D Expense Growth | +36.82% | +41.68% | +81.03% | +102.99% | +72.54% |
| SG&A Expenses Growth | +25.44% | +45.89% | +43.56% | +50.86% | +60.87% |